IBDEI1Z5 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31526,1,4,0)
 ;;=4^O36.1110
 ;;^UTILITY(U,$J,358.3,31526,2)
 ;;=^5016893
 ;;^UTILITY(U,$J,358.3,31527,0)
 ;;=O36.1111^^126^1626^38
 ;;^UTILITY(U,$J,358.3,31527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31527,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,1st tri,fts 1
 ;;^UTILITY(U,$J,358.3,31527,1,4,0)
 ;;=4^O36.1111
 ;;^UTILITY(U,$J,358.3,31527,2)
 ;;=^5016894
 ;;^UTILITY(U,$J,358.3,31528,0)
 ;;=O36.1112^^126^1626^39
 ;;^UTILITY(U,$J,358.3,31528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31528,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,1st tri,fts 2
 ;;^UTILITY(U,$J,358.3,31528,1,4,0)
 ;;=4^O36.1112
 ;;^UTILITY(U,$J,358.3,31528,2)
 ;;=^5016895
 ;;^UTILITY(U,$J,358.3,31529,0)
 ;;=O36.1113^^126^1626^54
 ;;^UTILITY(U,$J,358.3,31529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31529,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization1st tri,fts 3
 ;;^UTILITY(U,$J,358.3,31529,1,4,0)
 ;;=4^O36.1113
 ;;^UTILITY(U,$J,358.3,31529,2)
 ;;=^5016896
 ;;^UTILITY(U,$J,358.3,31530,0)
 ;;=O36.1114^^126^1626^40
 ;;^UTILITY(U,$J,358.3,31530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31530,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,1st tri,fts 4
 ;;^UTILITY(U,$J,358.3,31530,1,4,0)
 ;;=4^O36.1114
 ;;^UTILITY(U,$J,358.3,31530,2)
 ;;=^5016897
 ;;^UTILITY(U,$J,358.3,31531,0)
 ;;=O36.1115^^126^1626^41
 ;;^UTILITY(U,$J,358.3,31531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31531,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,1st tri,fts 5
 ;;^UTILITY(U,$J,358.3,31531,1,4,0)
 ;;=4^O36.1115
 ;;^UTILITY(U,$J,358.3,31531,2)
 ;;=^5016898
 ;;^UTILITY(U,$J,358.3,31532,0)
 ;;=O36.1120^^126^1626^42
 ;;^UTILITY(U,$J,358.3,31532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31532,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,2nd tri,unsp fts
 ;;^UTILITY(U,$J,358.3,31532,1,4,0)
 ;;=4^O36.1120
 ;;^UTILITY(U,$J,358.3,31532,2)
 ;;=^5016900
 ;;^UTILITY(U,$J,358.3,31533,0)
 ;;=O36.1121^^126^1626^43
 ;;^UTILITY(U,$J,358.3,31533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31533,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,2nd tri,fts 1
 ;;^UTILITY(U,$J,358.3,31533,1,4,0)
 ;;=4^O36.1121
 ;;^UTILITY(U,$J,358.3,31533,2)
 ;;=^5016901
 ;;^UTILITY(U,$J,358.3,31534,0)
 ;;=O36.1122^^126^1626^44
 ;;^UTILITY(U,$J,358.3,31534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31534,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,2nd tri,fts 2
 ;;^UTILITY(U,$J,358.3,31534,1,4,0)
 ;;=4^O36.1122
 ;;^UTILITY(U,$J,358.3,31534,2)
 ;;=^5016902
 ;;^UTILITY(U,$J,358.3,31535,0)
 ;;=O36.1123^^126^1626^45
 ;;^UTILITY(U,$J,358.3,31535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31535,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,2nd tri,fts 3
 ;;^UTILITY(U,$J,358.3,31535,1,4,0)
 ;;=4^O36.1123
 ;;^UTILITY(U,$J,358.3,31535,2)
 ;;=^5016903
 ;;^UTILITY(U,$J,358.3,31536,0)
 ;;=O36.1124^^126^1626^46
 ;;^UTILITY(U,$J,358.3,31536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31536,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,2nd tri,fts 4
 ;;^UTILITY(U,$J,358.3,31536,1,4,0)
 ;;=4^O36.1124
 ;;^UTILITY(U,$J,358.3,31536,2)
 ;;=^5016904
 ;;^UTILITY(U,$J,358.3,31537,0)
 ;;=O36.1125^^126^1626^47
 ;;^UTILITY(U,$J,358.3,31537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31537,1,3,0)
 ;;=3^Maternal care for Anti-A sensitization,2nd tri,fts 5
 ;;^UTILITY(U,$J,358.3,31537,1,4,0)
 ;;=4^O36.1125
 ;;^UTILITY(U,$J,358.3,31537,2)
 ;;=^5016905
